Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Acquires 4,815 Shares of Stock

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis purchased 4,815 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were bought at an average price of $4.15 per share, with a total value of $19,982.25. Following the completion of the transaction, the director now owns 37,508 shares of the company’s stock, valued at $155,658.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Rezolute Stock Performance

Shares of RZLT traded up $0.01 during midday trading on Thursday, hitting $4.01. The company had a trading volume of 214,733 shares, compared to its average volume of 498,249. The company’s 50-day simple moving average is $3.63 and its 200-day simple moving average is $2.25. Rezolute, Inc. has a 1 year low of $0.72 and a 1 year high of $6.10. The firm has a market capitalization of $160.92 million, a P/E ratio of -3.50 and a beta of 1.31.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.34) EPS for the quarter, hitting the consensus estimate of ($0.34). Equities analysts predict that Rezolute, Inc. will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in Rezolute in the first quarter valued at approximately $37,000. Affinity Asset Advisors LLC acquired a new position in shares of Rezolute in the 1st quarter valued at $4,080,000. Acadian Asset Management LLC purchased a new position in shares of Rezolute in the 1st quarter valued at $229,000. Vanguard Group Inc. raised its stake in Rezolute by 10.4% during the 1st quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock worth $3,961,000 after acquiring an additional 145,700 shares in the last quarter. Finally, Rosalind Advisors Inc. purchased a new stake in Rezolute in the first quarter valued at $510,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RZLT. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Rezolute in a research report on Wednesday, May 22nd. Maxim Group started coverage on Rezolute in a research note on Tuesday, April 9th. They set a “buy” rating and a $8.00 target price on the stock. Jonestrading started coverage on Rezolute in a report on Thursday, April 18th. They set a “buy” rating and a $10.00 target price for the company. Craig Hallum assumed coverage on shares of Rezolute in a research note on Tuesday, June 4th. They set a “buy” rating and a $14.00 price target on the stock. Finally, JMP Securities reissued a “market outperform” rating and issued a $7.00 price objective on shares of Rezolute in a research note on Thursday, April 18th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Rezolute currently has a consensus rating of “Buy” and a consensus target price of $9.67.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.